Efficacy and safety of a novel formulation of an oral fumarate, BG-12, in patients with moderate to severe plaque psoriasis: Results of a phase III study

doi:10.1016/j.jaad.2004.10.740

Efficacy and safety of a novel formulation of an oral fumarate, BG-12, in patients with moderate to severe plaque psoriasis: Results of a phase III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2004.10.740 ◽

2005 ◽

Vol 52 (3) ◽

pp. P182

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study

The Journal of Dermatology ◽

10.1111/1346-8138.13900 ◽

2017 ◽

Vol 44 (10) ◽

pp. 1129-1137 ◽

Cited By ~ 14

Author(s):

Nan-Lin Wu ◽

Chih-Jung Hsu ◽

Fang-Ju Sun ◽

Tsen-Fang Tsai

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Drugs & Aging ◽

10.1007/s40266-018-0520-z ◽

2018 ◽

Vol 35 (2) ◽

pp. 135-144 ◽

Cited By ~ 23

Author(s):

Andreas Körber ◽

Charis Papavassilis ◽

Vaishali Bhosekar ◽

Maximilian Reinhardt

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase Iii ◽

Elderly Subjects ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Studies

Download Full-text

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

American Journal of Clinical Dermatology ◽

10.1007/s40257-018-0353-x ◽

2018 ◽

Vol 19 (3) ◽

pp. 457-457 ◽

Cited By ~ 1

Author(s):

Andrew Blauvelt ◽

Kim A. Papp ◽

Christopher E. M. Griffiths ◽

Luis Puig ◽

Jamie Weisman ◽

...

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Randomized Clinical Trials ◽

Phase Iii ◽

Efficacy And Safety ◽

Two Phase ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.010 ◽

2004 ◽

Vol 50 (3) ◽

pp. P1 ◽

Cited By ~ 5

Author(s):

Kenneth Gordon ◽

David Pariser ◽

Richard Langley ◽

Ivor Caro

Keyword(s):

Plaque Psoriasis ◽

Large Cohort ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Trials

Download Full-text

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

British Journal of Dermatology ◽

10.1111/bjd.16426 ◽

2018 ◽

Vol 178 (6) ◽

pp. 1315-1323 ◽

Cited By ~ 23

Author(s):

R.G. Langley ◽

K. Papp ◽

M. Gooderham ◽

L. Zhang ◽

C. Mallinckrodt ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Severe Plaque Psoriasis

Download Full-text

A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.08.066 ◽

2021 ◽

Author(s):

Nina Magnolo ◽

Külli Kingo ◽

Vivian Laquer ◽

John Browning ◽

Adam Reich ◽

...

Keyword(s):

Multicenter Study ◽

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis

Download Full-text